

17 June 2026

**Coiled Therapeutics plc**  
("Coiled Therapeutics" or the "Company")

**Grant of Share Options**

Coiled Therapeutics (AIM:COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces it has granted 6,200,000 share options ("Options") over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to certain employees, advisors and persons discharging managerial responsibilities ("PDMRs").

The Options, which have been granted under the Company's existing share option scheme and have an exercise price of 10.0 pence each.

**Schedule of Options granted to PDMRs**

<i>Name</i>	<i>Number of Options granted</i>	<i>Vesting period</i>
Dr Andrew Dean ( <i>Non-Executive Director</i> )	4,000,000	2,000,000 after 6 months 2,000,000 after 12 months
Robbin Frnka ( <i>Chief Clinical Operations</i> )	2,000,000	Equal portions over three years

The remaining 200,000 Options have been granted to a scientific advisor of the Company and will vest on the same terms as Mrs Frnka's described above.

**Enquiries:**

**Coiled Therapeutics plc**

Sotirios Stergiopoulos (Chairman)

Sridhar Vempati (CEO)

Via Burson

Buchanan

**SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker)**

+44 (0)20 3470 0470

David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

**Shard Capital Partners LLP (Joint Broker)**

+44 (0)20 4530 6926

Damon Heath

**CPS Capital Group Pty Ltd (Joint Broker)**

+61 (0)8 9223 2222

Jason Peterson / David Valentino

**Burson Buchanan (Public Relations)**

+44 (0)20 7466 5000

Henry Harrison Topham / Jamie Hooper / Toto Berger

**Harbor Access (US Investor Relations)**

+1 475 477 9404

Matt Kelly / Jonathan Paterson

## About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage oncology company focused on developing innovative precision therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, a key differentiator that may enable treatment of both primary brain tumours and brain metastases, areas of significant unmet medical need. Preclinical and early clinical observations support further evaluation of the programme's potential across multiple tumour types.

AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study in the United States. Early clinical observations have demonstrated encouraging anti-tumour activity and a favourable safety profile, with the Company planning to initiate dose expansion cohorts in selected indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: [www.coiledplc.com](http://www.coiledplc.com) and follow us on [LinkedIn](#).

### Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name:	1) Dr Andrew Dean 2) Robbin Frnka
2.	<b>Reason for the notification</b>	
a)	Position/status:	1) Non-Executive Director 2) Chief Clinical Operations
b)	Initial notification/Amendment:	Initial notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name:	Coiled Therapeutics Plc
b)	LEI:	254900P4SISIWOR9RH34
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary Shares of 1 pence

		GB00BSHRN331
b)	Nature of the transaction:	Grant of Options
c)	Price(s) and volume(s):	1) 4,000,000 10.0 pence
		2) 2,000,000 10.0 pence
d)	Aggregated information: Aggregated volume: Price:	Single transaction as in 4 c) above
e)	Date of the transaction:	16 June 2026
f)	Place of the transaction:	Off market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUBOWRNNUNARR